Breaking News
February 17, 2019 - MUSC researchers discover new mechanism for a class of anti-cancer drugs
February 17, 2019 - HPV misconceptions are causing women to miss smear tests
February 17, 2019 - Sanofi and Regeneron Offer Praluent (alirocumab) at a New Reduced U.S. List Price
February 17, 2019 - Researchers say auditory testing can identify children for autism screening
February 17, 2019 - New method analyzes how single biological cells react to stressful situations
February 17, 2019 - WVU gynecologic oncologist investigates novel treatment for cervical and vaginal cancers
February 17, 2019 - ADHD diagnoses poorly documented
February 17, 2019 - Majority of gender minority youth do not identify with traditional sexual identity labels
February 17, 2019 - AbbVie, Teneobio enter into strategic transaction to develop potential treatment for multiple myeloma
February 17, 2019 - Lower Birth Weight May Up Risk for Psychiatric Disorders
February 17, 2019 - Scientists identify reversible molecular defect underlying rheumatoid arthritis
February 17, 2019 - Moffitt researchers shed light on how CAR T cells function mechanistically
February 16, 2019 - Female Anatomy May Play Big Role in Sperm’s Success
February 16, 2019 - BMI may mediate inverse link between fiber intake, knee OA
February 16, 2019 - Movement impairments in autism can be reversed through behavioral training
February 16, 2019 - Studies address racial disparities in postpartum period and cardiovascular health
February 16, 2019 - Scientists implicate hidden genes in the severity of autism symptoms
February 16, 2019 - Decreased deep sleep linked to early signs of Alzheimer’s disease
February 16, 2019 - Neuroscientists show how the brain responds to texture
February 16, 2019 - Gilead Announces Topline Data From Phase 3 STELLAR-4 Study of Selonsertib in Compensated Cirrhosis (F4) Due to Nonalcoholic Steatohepatitis (NASH)
February 16, 2019 - What Can I Do About Sweating? (for Teens)
February 16, 2019 - Companies navigate dementia conversations with older workers
February 16, 2019 - Newly developed stem cell technologies show promise for treating PD patients
February 16, 2019 - Collaborative material research could advance self-assembling nanomaterials
February 16, 2019 - Researchers take major step in creating technology that mimics the human brain
February 16, 2019 - Erasing memories associated with cocaine use reduces drug seeking behavior
February 16, 2019 - Artificial intelligence can accurately predict prognosis of ovarian cancer patients
February 16, 2019 - Racial disparities in cancer deaths on the decline for America
February 16, 2019 - FDA authorizes new interoperable insulin pump for children, adults with diabetes
February 16, 2019 - Coexisting Medical Conditions, Smoking Explain PTSD-CVD Link
February 16, 2019 - Skin Cancer Screening: MedlinePlus Lab Test Information
February 16, 2019 - ‘Happiness’ exercises can boost mood in those recovering from substance use disorder
February 16, 2019 - Cell manipulation could soon halt or reverse aging
February 16, 2019 - Pumped Breast Milk Falls Short of Breastfed Version
February 16, 2019 - Men’s porn habits could fuel partners’ eating disorders, study suggests
February 16, 2019 - Rapid progression of age-related diseases may result from formation of vicious cycles
February 16, 2019 - Immune checkpoint molecule protects against future development of cancer
February 16, 2019 - New method produces hydrogels that have properties similar to cells’ environment
February 16, 2019 - $4.1 million funding for heart research on Valentine’s Day
February 16, 2019 - General anesthesia in early infancy unlikely to have lasting effects on developing brains
February 16, 2019 - New breakthroughs for muscular dystrophy research
February 16, 2019 - First Opinion: Embryo editing for higher IQ is a fantasy. Embryo profiling for it is almost here
February 16, 2019 - Vapers develop cancer-related gene deregulation as cigarette smokers
February 16, 2019 - Bringing Antimicrobial Susceptibility Testing (AST) to the Community
February 16, 2019 - Decolonization protocol after hospital discharge can prevent dangerous infections
February 16, 2019 - Children with ASD more likely to face maltreatment, study finds
February 16, 2019 - Study finds genetic vulnerability to use of menthol cigarettes
February 16, 2019 - H-RT should be the standard of care for men with low risk prostate cancer, study shows
February 16, 2019 - New technique using patients’ own modified cells could help treat Crohn’s disease
February 16, 2019 - Therapeutic endoscopy has an expanding role in the treatment of IBD
February 16, 2019 - Blood clot discovery could lead to development of better treatments for blood diseases
February 16, 2019 - Intervention can increase exclusive breastfeeding rates
February 16, 2019 - New project explores how gaming technologies can help cancer patients communicate better
February 16, 2019 - Catalyst Biosciences Presents Updated Data from Its Phase 2/3 Trial of Subcutaneous Marzeptacog Alfa (Activated) in Individuals with Hemophilia A or B with Inhibitors at the 12th Annual EAHAD Congress
February 16, 2019 - Rerouting nerves during amputation reduces phantom limb pain before it starts
February 16, 2019 - A Hormone Produced When We Exercise Might Help Fight Alzheimer’s
February 16, 2019 - Millions of British people breathe toxic air travelling to GPs
February 16, 2019 - Conformance of genetic characteristics found to be crucial for longer preservation of kidney graft
February 16, 2019 - Researchers use optogenetic tool to control, visualize receptor signals in neural cells
February 16, 2019 - New reversible antiplatelet therapy could reduce risk of blood clots, prevent cancer metastasis
February 16, 2019 - Testosterone is not the only hormone needed for penis development
February 16, 2019 - FDA Advisory Committee Recommends Approval of Spravato (esketamine) Nasal Spray for Adults with Treatment-Resistant Depression
February 15, 2019 - Heart surgery technology developed at Baptist Health debuts after years of secrecy
February 15, 2019 - Prescription Opioids Double Risk of Triggering Fatal Car Crash
February 15, 2019 - New study helps doctors better understand high blood pressure in pregnant women
February 15, 2019 - Beta wave control in Parkinson’s diseased brain could be a potential therapy
February 15, 2019 - Media representations of love may justify gender-based violence in young people
February 15, 2019 - Yoga May Help With Rheumatoid Arthritis Symptoms, Severity
February 15, 2019 - Obstructive sleep apnea linked to inflammation, organ dysfunction
February 15, 2019 - Master your mind: A challenge from WELL for Life
February 15, 2019 - Why Some Brain Tumors Respond to Immunotherapy
February 15, 2019 - Must-Reads Of The Week From Brianna Labuskes
February 15, 2019 - Researchers uncover novel mechanism and potential new therapeutic target for Alzheimer’s
February 15, 2019 - Genetic variations in a fourth gene associated with higher ALL risk in Hispanic children
February 15, 2019 - Disruptive behavioral problems in kindergarten linked with lower employment earnings in adulthood
February 15, 2019 - New bioengineered device enhances the production of T-cells
February 15, 2019 - HDL proteome behaves like a tiny Velcro ball that is rolling on surfaces
February 15, 2019 - Puerto Rican children more likely to have poor or decreasing use of asthma inhalers
February 15, 2019 - Quality of patient care does not improve after physician-hospital integration
February 15, 2019 - Synopsys release new software for implant design and patient-specific planning
Research shows enlarged genotype-phenotype correlation for three-base pair deletion in NF1

Research shows enlarged genotype-phenotype correlation for three-base pair deletion in NF1

image_pdfDownload PDFimage_print

International collaborative research led by Ludwine Messiaen, Ph.D., shows that while a three-base pair, in-frame deletion called p.Met992del in the NF1 gene has a mild phenotype for people with the genetic disorder neurofibromatosis type 1, or NF1, the mutation does cause complications. These include non-optic brain tumors, mostly low-grade and asymptomatic, as well as cognitive impairment and/or learning disabilities. This study extends findings first reported in 2007 that included only 19 NF1 adults.

“Learning difficulties are clearly part of the phenotypic presentation in these individuals and will require specialized care,” said Messiaen, professor of genetics and director of the Medical Genomics Laboratory at the University of Alabama at Birmingham.

Including more adults in the new study was the key to obtaining statistically significant evidence of a mild phenotype that included absence of cutaneous and externally visible plexiform neurofibromas and symptomatic optic pathway gliomas. This is important because whether patients will have mild or severe disease cannot — in most cases — be predicted when the neurofibromatosis type 1 first appears, often only with café-au-lait skin markings in infants.

As the patients grow, they typically show a broad clinical variability, especially at the beginning of puberty, when many benign skin tumors called cutaneous neurofibromas erupt as bumps across the body and increase in number, even to thousands, over time.

Patients vary widely in their symptoms, which can include freckles in skin folds of the body, benign nodules in the iris of the eyes, tumors along the optic nerve, heart defects, bone anomalies, developmental delay, intellectual disability and learning problems. Although cutaneous neurofibromas never become malignant, they have a huge negative impact on the quality of life due to the disfigurement and associated pruritus.

On the other hand, plexiform neurofibromas not only cause disfigurement, pain and neurological deficits, but also may become malignant, resulting in significant morbidity of these individuals. They are found in about 15 to 30 percent of NF1 patients and are usually apparent in the early years of life. Therefore, it is critical to identify as early as possible those individuals with an increased risk to develop malignancies in order to provide personalized management and genetic counseling.

“Patients and their families want to know what may happen,” Messiaen said. “When a child is born with neurofibromatosis type 1, the café-au-lait spots appear early in life, sometimes as the only clinical feature of NF1. But many other problems, more specifically the development of cutaneous neurofibromas, may occur later, typically around puberty. If a genotype-phenotype correlation exists for a particular mutation, it will help these families have a better idea of what the future will bring, and it will help families cope with the disease.”

Knowing what to expect from a particular NF1 mutation can help guide clinical management and genetic counseling in this complex condition, which is caused by one out of more than 3,000 different mutations found so far, distributed in every part of this large NF1 gene.

Although clinically useful genotype-phenotype correlations will not exist for the majority of the NF1 pathogenic variants, every such association between specific recurrent mutations and specific symptoms will impact many lives.

Finding a novel genotype-phenotype correlation is challenging. It is hampered by issues such as the variability of the clinical presentation, the age-dependency of most manifestations and the vast number of different NF1 pathogenic variants. More than 2,500 of these variants have so far been identified in only one or two unrelated individuals.

A group of pathogenic variants called missense and single amino acid deletions are promising candidates for finding additional genotype-phenotype correlations, as they typically change only a very small portion of the protein and may affect protein functionality in a more specific way.

“My research currently prioritizes on the most recurrent missense mutations and single amino acid deletions that have a frequency of more than 0.5 percent in the UAB cohort,” Messiaen said. “This approach so far has led to the identification of three clinically relevant genotype-phenotype correlations that together impact the lives of 2 to 3 percent of all NF1 patients.”

Massive effort

To look for correlations, Messiaen and her team collected detailed clinical information on all symptoms found in each of 135 NF1-affected individuals from 103 unrelated families who had the p.Met992del mutation identified at the UAB Medical Genomics Laboratory and collaborating European centers. Then, these data were compared to several large clinical cohorts previously reported in the literature.

Their study, published in the journal Genetics in Medicine, involved 70 researchers and clinicians from 47 hospitals and universities in the United States, Belgium, Italy, Spain, the Netherlands, Australia, Austria and Canada.

The researchers found that none of the individuals had externally visible histopathologically confirmed cutaneous or plexiform neurofibromas, and none had complications like symptomatic optic pathway gliomas or symptomatic spinal neurofibromas. However, 4.8 percent of the study group had mostly low-grade, asymptomatic non-optic brain tumors, and 38.8 percent had cognitive impairment and/or learning disabilities.

The protein encoded by NF1 is a string of 2,818 amino acids that folds into the protein shape. Although the NF1 gene was cloned in 1990, the cellular functions performed by the huge, multi-domain protein encoded by the gene, and called neurofibromin, are still incompletely understood. As such, the specific function of the NF1 codon 992 affected by the p.Met992del deletion remains so far unknown.

Neurofibromatosis type 1 is a common genetic disorder with highly variable symptoms, and it occurs in one out of every 2,000 to 3,000 births. The UAB Medical Genomics Laboratory has collected DNA and identified a pathogenic mutation on the more than 10,000 unrelated NF1 patients. These include more than 3,000 different mutations, and the mutational spectrum involves microdeletions, deletions or duplications of one or more exons, frameshift and nonsense mutations, and splice or missense mutations.

Although only four groups of recurrent mutations with clear genotype-phenotype correlations have been reported so far, each accounting for only a small percentage of NF1-affected individuals, they together affect between 5 and 10 percent of the neurofibromatosis type 1 population.

“This is already a significant fraction; but there is still a lot of work to do, and more remain to be identified,” said first author Magdalena Koczkowska, Ph.D. “Close collaboration between NF1 clinicians and molecular geneticists is critical to achieve a timely unfolding of additional correlations that will allow genotype-driven personalized medicine.”

Source:

https://www.uab.edu/news/research/item/9741-enlarged-genotype-phenotype-correlation-for-a-three-base-pair-deletion-in-neurofibromatosis-type-1

Tagged with:

About author

Related Articles